Respiratory Medicine
Volume 104, Issue 2 , Pages 253-259 , February 2010

Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study

  • P. Almagro

      Affiliations

    • Internal Medicine Service, Hospital Mútua de Terrassa, Plaza Dr. Robert 5, 08221 Terrassa, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Internal Medicine Service, Hospital Mútua de Terrassa. Plaza Dr. Robert 5, 08221 Terrassa, Barcelona, Spain. Tel.: +34 937365050.
    • ,
  • F. López García

      Affiliations

    • Internal Medicine Service, Hospital Vega Baja-Orihuela, Alicante, Spain
    • ,
  • FJ. Cabrera

      Affiliations

    • Internal Medicine Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
    • ,
  • L. Montero

      Affiliations

    • Internal Medicine Service, Hospital Comarcal Axarquía. Vélez Málaga, Málaga, Spain
    • ,
  • D. Morchón

      Affiliations

    • Internal Medicine Service, Hospital Universitario del Rio Hortega, Valladolid, Spain
    • ,
  • J. Díez

      Affiliations

    • Internal Medicine Service, Hospital Royo Villanova, Zaragoza, Spain
    • ,
  • JB. Soriano

      Affiliations

    • Programa de Epidemiología e Investigación Clínica, Fundación Caubet-CIMERA, Centro Internacional de Medicina Respiratoria Avanzada, Baleares, Spain
    • ,
  • GRUPO EPOC DE LA SOCIEDAD ESPAÑOLA DE MEDICINA INTERNA

Received 9 May 2009 ,Accepted 28 September 2009.

References 

  1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–750
  2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442
  3. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonarydisease – 2007 update. Can Respir J. 2007;14:S5–S32
  4. Mannino DM, Homa DM, AkinBami LJ, et al. Chronic obstructive pulmonary disease surveillance-United States, 1971–2000. MMWR Surveill Summ. 2002;51:1–16
  5. Global Strategy for the Diagnosis . Management and Prevention of COPD, global Initiative for chronic obstructive lung disease (GOLD). [consulted 29th November 2008]. Available at http://www.goldcopd.org2008;
  6. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  7. Sin DD, Anthonisen NR, Soriano JB, Agustí AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28:1245–1257
  8. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555
  9. Rodriguez-Roisin Soriano JB. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proc Am Thorac Soc. 2008;5:842–847
  10. Celli BR, MacNee W. American Thoracic Society / European respiratory Society Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  11. de Torres JP, Casanova C, Hernández C, et al. Gender and COPD in patients attending a pulmonary clinic. Chest. 2005;128:2012–2016
  12. de Torres JP, Cote CG, López MV, et al. Sex differences in mortality in patients with COPD. Eur Respir J. 2009;33:528–535
  13. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251
  14. Almagro P, Calbo E, Ochoa de Echagüen A, et al. Mortality after hospitalization for COPD. Chest. 2002;121:1441–1448
  15. Torres JP, Casanova C, Montejo de Garcini A, et al. Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respir Res. 2007;8:18
  16. Carrasco-Garrido P, de Miguel-Díez J, Rejas-Gutierrez J, et al. Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspective. BMC Pulm Med. 2009;9:2–16
  17. Almagro P, López García F, Cabrera FJ, et al. Estudio de las comorbilidades en pacientes hospitalizados por descompensación de EPOC atendidos en los servicios de Medicina Interna. Estudio ECCO Rev Clin Esp (in press).
  18. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204
  19. Jørgensen NR, Schwarz P, Holme I, et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med. 2007;101:177–185
  20. Pinckney RG, O'Brien RO, Piccirillo JF, Littenberg B. Evaluation of co-morbidity indices in patients admitted for chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 2004;61(4):209–212
  21. Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167:60–67
  22. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J. 2008;32:962–969
  23. Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser permanente medical Care program. Chest. 2005;128:2068–2075
  24. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005–2011
  25. Render ML, Weinstein AS, Blaustein AS. Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. Chest. 1995;107:162–168
  26. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519
  27. Bale G, Martinez-Camblor Burge PS, Soriano JB. Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respir Med. 2008;102:1468–1472
  28. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434–1440
  29. Gray-Donald K, Gibbons L, Shapiro SH, et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:961–966
  30. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119:1691–1695
  31. WHO Atlas of smoking worldwide 2003. At www.who.int/tobacco/statistics/tobacco_atlas/en/. Consulted 3rd March 2009.
  32. García-Aymerich J, Barreiro E, Farrero E, et al. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J. 2000;16:1037–1042

PII: S0954-6111(09)00318-7

doi: 10.1016/j.rmed.2009.09.019

Respiratory Medicine
Volume 104, Issue 2 , Pages 253-259 , February 2010

Article Tools

* Image Usage & Resolution